CLASSIFICATION CONFIDENTIAL
SECURITY INFORMATION
CENTRAL INTELLIGENCE AGENCY
INFORMATION FROM
FOREIGN DOCUMENTS OR RADIO BROADCASTS

REPORT
CD NO.

50X1-HUM

COUNTRY USSR

SUBJECT Scientific - Medicine, leukopenia, effects of radiation

DATE OF INFORMATION 1952

HOW PUBLISHED Monthly periodicals

DATE DIST. 8 Dec 1952

WHERE PUBLISHED Moscow

NO. OF PAGES 3

DATE PUBLISHED Jul 1952

LANGUAGE Russian

SUPPLEMENT TO REPORT NO.

THIS IS UNEVALUATED INFORMATION

SOURCE Periodicals as indicated.

NEW USSR DRUG TEZAN-25 (THESANUM)

/The following information has been taken from an advertisement published by Soyuzglavaptekoupravleniye (All-Union Main Pharmacy Administration) in Klinicheskaya Meditsina and an item that appeared under the caption "New Drugs" in the medical journal Khirurgiya./

The Medical Industry Section of the Ministry of Public Health USSR has released a new product, Tezan-25, which will be sent on request to pharmacy administrations. This product has been developed by the All-Union Scientific Research Chemicopharmaceutical Institute imeni S. Ordzhonikidze.

Tezan-25 is a white crystalline powder which is readily soluble in alcohol and soluble with difficulty in cold water. This compound is very stable and may be stored over long periods of time. It does not decompose under the action of heat and withstands sterilization in the autoclave.

Tezan-25 is supplied in tablets, powder form, and ampules. The tablets contain 5 mg, 10 mg, or 20 mg each of the compound. The powder form is packaged in glass vials containing 5 or 10 g each. Ampules contain a sterile 0.1% solution in 1 or 2 ml of solvent.

When used in liquid form, Tezan is dissolved in alcohol. A solution of 0.5 g of the compound per 100 ml of 20% alcohol is prepared for that purpose.

Use of Tezan is indicated in leukopenia caused by chemotherapy and radiation /from X-rays and radium/, and in leukopenias arising from toxic conditions such as agranulocytic angina and varied infections.

The application of Tezan in diseases of the bone marrow, such as neoplasms, is not indicated.

Administration of Tezan is controlled by frequent blood examinations.

CLASSIFICATION CONFIDENTIAL

STATE	X	NAVY	X	NSRB		DISTRIBUTION													
ARMY	X	AIR	X	FBI															



Administration of Tezan in conjunction with radiation and chemical therapy should be started preferably before the number of leucocytes has dropped. This combined treatment can be safely maintained as long as the number of leucocytes in 1 sq mm of peripheric blood does not fall below 3,600. If this figure is reached, radiation and chemical therapy treatments should be suspended and resumed only when the blood count shows a leucocyte figure of 4,000.

Observations have revealed that Tezan is not habit-forming; consequently, it can be used for lengthy periods of time. In cases of recurrent leukopenia, treatment with Tezan can be repeated without any reduction of the therapeutic effect.

Tezan may be administered simultaneously with other drugs, or simultaneously with blood transfusions.

The use of Tezan is counterindicated in conjunction with medications acting as depressants of thermopoiesis, i.e., sulfamides, pyramidon, etc.

Tezan may be used not only in cases of leukopenia, but also in cases of general depression of the body. As a rule, administration of Tezan produces an increase in appetite and a feeling of well-being. It is on these grounds that the experimental use of Tezan in other diseases is recommended.

Treatment with Tezan is usually started by oral administration of a 0.5% solution in doses of 10 or 20 drops in a dessert or soup spoon full of water. The tablets may be given every 6 or 8 hr before meals. If after 10 or 12 days of this treatment there is no increase of leucocytes in the peripheric blood of the patient, oral administration of Tezan should be replaced by intramuscular injections of 1 ml of a 0.1% solution every 8 hr.

The following are sample prescriptions:

Rx Sol Thesani 0.1% - 1.0

D.t.d. in ampuli No 50

S. For injection of 1 ml q 6 h

Rx Sol Thesani 0.5% - 20.0

DS 10-20 gtts in a wine glass of water q 3 h or q 4 h ac

Rx Thesani 0.01

D.t.d. in tablets No 50

S. One tablet t.i.d. or q.i.d.

This drug has been tested at the Central Institute of Roentgenology and Radiology imeni V. M. Molotov; the Central Oncological Institute imeni Gertsen; the Institute of Oncology, Academy of Medical Sciences USSR; the Oncological Department, "Medsantrud" Hospital; the Surgical Department, Noginsk City Hospital; and the Neurological Department, Moscow Oblast Scientific Research Clinical Institute (MONIKI). Release of this drug has been authorized by the Pharmacological Committee of the Scientific Medical Council (Ucheny Meditsinsky Sovet), Ministry of Public Health USSR (Protocol No 9 of 15 April 1950).

If this compound is unobtainable in any particular locality, it can be requested from the oblast or kray pharmacy administration. Anyone unable to obtain the product from this source can forward a request to "Khimfarmsbyt" Moscow, Bol'shoy Chudov Per No 8, or to the office of "Rosmedsnabtorg" Moscow, 1st Kolobovskiy Per No 19, or to "Medtorg," Main Pharmacy Administration Ukrainian SSR, Kiev, Ulitsa Kominterna No 16.

- E N D -